Streetbeat News

Revenues

TGI

Triumph Group projects its Q4 2024 revenue to be in the range of $336.5M to $366.5M, compared to the estimated $354.946M by analysts.

Portfolio Pulse from Benzinga Newsdesk

March 08, 2024 | 9:15 pm

TGI

Triumph Group has reaffirmed its fiscal year 2024 revenue guidance to be in the range of $1.17 billion to $1.20 billion, which is below the estimated $1.238 billion.

Portfolio Pulse from Benzinga Newsdesk

March 08, 2024 | 9:15 pm

DIS

Disney CEO Bob Iger announced that ESPN will continue to leverage its linear TV presence for revenue and profits while transitioning to streaming, according to Reuters.

Portfolio Pulse from Benzinga Newsdesk

March 08, 2024 | 8:35 pm

GDX

GLD

IAU

SGOL

Global physically backed gold ETFs have experienced outflows for nine consecutive months, totaling $5.7 billion year-to-date, despite gold prices reaching all-time highs. The outflows are primarily from North America, with factors such as a strong labor market, higher inflation, and a potential Federal Reserve rate cut contributing to the trend. However, gold prices continue to rise due to speculative betting and physical demand, particularly from China. Central bank demand remains strong, supporting gold prices. Gold ETFs mentioned include SPDR Gold Trust (GLD), iShares Gold Trust (IAU), Abrdn Physical Gold Shares ETF (SGOL), and VanEck Gold Miners (GDX).

Portfolio Pulse from Stjepan Kalinic

March 08, 2024 | 8:31 pm

IGMS

IGM Biosciences (NASDAQ:IGMS) has seen a variety of analyst opinions over the past three months, with recent ratings showing a shift towards a more bullish outlook. Analysts have set a 12-month price target average of $17.5 for IGMS, marking a significant increase from the previous $9.00 average. This change reflects a positive sentiment based on the company's performance and market conditions. IGM Biosciences is a biotech firm focused on developing antibody therapeutics for various diseases, showing strong revenue growth but facing challenges in net margin, ROE, and ROA.

Portfolio Pulse from Benzinga Insights

March 08, 2024 | 8:01 pm

MEDP

Medpace Holdings (NASDAQ:MEDP) has received diverse analyst ratings over the last three months, with a shift towards a more bullish outlook. The average 12-month price target for MEDP has increased by 22.55% to $413.0. Analysts from UBS and Baird have raised their price targets, reflecting positive sentiment towards the company's performance, including a solid revenue growth rate of 26.47% and a high net margin of 15.7%. Medpace, a contract research organization, has shown strong financial management with an ROE of 15.2% and an ROA of 4.98%.

Portfolio Pulse from Benzinga Insights

March 08, 2024 | 8:01 pm

FHI

Seven analysts have recently updated their ratings on Federated Hermes (NYSE:FHI), showing a mix of perspectives with an average 12-month price target of $37.14, up from $36.80. The updates include raised price targets and ratings, reflecting a cautiously optimistic outlook on the company's performance. Federated Hermes, with $757.6 billion in managed assets, shows a positive revenue trend and strong financial performance indicators such as ROE and ROA, despite a market capitalization below industry averages and a net margin below benchmarks.

Portfolio Pulse from Benzinga Insights

March 08, 2024 | 8:00 pm

EYPT

EyePoint Pharmaceuticals (NASDAQ:EYPT) has received diverse analyst ratings over the past quarter, with a shift towards more bullish sentiments in the last 30 days. The average 12-month price target for EYPT has increased by 12.64% to $36.8, with a high estimate of $44.00 and a low estimate of $33.00. Financial analysis reveals a positive revenue trend with a growth rate of 51.84% as of September 30, 2023, but challenges in net margin, ROE, and ROA. The company's debt-to-equity ratio is below industry average, indicating a conservative financial approach.

Portfolio Pulse from Benzinga Insights

March 08, 2024 | 8:00 pm

AAPL

GFS

NVDA

TSM

Taiwan Semiconductor Manufacturing Corp. (TSMC) is expected to receive up to $5 billion in grants from the U.S. government for a chip fabrication facility in Arizona to meet the demand from major customers like Apple and Nvidia. The facility is part of TSMC's $40 billion investment in semiconductor manufacturing in Phoenix, aiming to start production in 2025. This move aligns with the U.S. CHIPS Act's goal to boost domestic semiconductor production.

Portfolio Pulse from Neil Dennis

March 08, 2024 | 7:39 pm

BC

Seven analysts have recently updated their ratings on Brunswick (NYSE:BC), showing a shift towards a more bullish outlook with an average 12-month price target of $105.71, up from $95.50. The updates include raised price targets and ratings, reflecting positive sentiment towards Brunswick's market position despite a -13.95% decline in revenue growth and a high debt-to-equity ratio. Brunswick is recognized for its innovation in the marine recreation industry, with a strong market capitalization and financial health indicators like net margin, ROE, and ROA outperforming industry averages.

Portfolio Pulse from Benzinga Insights

March 08, 2024 | 7:01 pm